<DOC>
	<DOCNO>NCT01804959</DOCNO>
	<brief_summary>SSc-associated gastrointestinal ( GI ) involvement common , effective treatment . Probiotics may beneficial effect symptom support one small open-label study ( n=10 ) demonstrate decreased bloating symptom SSc patient 2 month probiotic . This study aim determine ( ) whether 60 day VSL # 3 probiotic result great GI symptom improvement placebo SSc outpatient , assess use interview-administered 34-item Gastrointestinal Tract ( GIT ) questionnaire ( ii ) whether 60 day versus 120 day probiotic result great GI symptom improvement SSc outpatient , assess use GIT questionnaire .</brief_summary>
	<brief_title>Clinical Trial Probiotics Systemic Sclerosis Associated Gastrointestinal Disease</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<criteria>SSc fulfills American College Rheumatology ( ACR , 1990 ) classification criterion propose European League Against Rheumatism ( EULAR ) criteria early diagnosis systemic sclerosis . SSc overlap syndrome ( ie SSc occur overlap connective tissue disease ) SScassociated GI symptom ( heartburn , dysphagia , vomit , bloating/distension , faecal soilage , diarrhoea , constipation ) due cause determine clinical evaluation , total GIT score least 0.10 Stable dos immunosuppressive treatment , corticosteroid , GI medication 30 day . On antibiotic probiotic within last 30 day Current serious infection require hospitalization Longterm indwelling catheter , include patient total parenteral nutrition Females lactating pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>